Disclosed are compositions containing at least 10% w/w or above of 1-O-galloyl-β-D-glucose (β-glucogallin) which additionally comprising of about 10% w/w to greater than 60% w/w total mucic acid gallates including mucic acid 1,4-lactone 5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-Methyl ester 2-O-gallate, mucic acid 1-Methyl ester 2-O-gallate and ellagic acid, and a probiotic bacteria Bacillus coagulans MTCC 5856, individually or in combination for inhibiting the growth and managing infections of Helicobacter pylori.